

Hydrolysis of chiral organophosphorus compounds by phosphotriesterases and mammalian paraoxonase-1

Antonio Monroy-Noyola¹, Damianys Almenares-Lopez², Eugenio Vilanova Gisbert³

¹Laboratorio de Neuroproteccion, Facultad de Farmacia, Universidad Autonoma del Estado de Morelos, Morelos, Mexico, ²Division de Ciencias Basicas e Ingenierias, Universidad Popular de la Chontalpa, H. Cardenas, Tabasco, Mexico, ³Instituto de Bioingenieria, Universidad Miguel Hernandez, Elche, Alicante, Spain

TABLE OF CONTENTS

1. Abstract
2. Introduction
 - 2.1. Organophosphorus compounds (OPs) and their toxicity
 - 2.2. Metabolism and treatment of OP intoxication
 - 2.3. Chiral OPs
3. Stereoselective hydrolysis
 - 3.1. Stereoselective hydrolysis determines the toxicity of chiral compounds
 - 3.2. Hydrolysis of nerve agents by PTEs
 - 3.2.1. Hydrolysis of V-type agents
 - 3.3. PON1, a protein restricted in its ability to hydrolyze chiral OPs
 - 3.4. Toxicity and stereoselective hydrolysis of OPs in animal tissues
 - 3.4.1. The calcium-dependent stereoselective activity of OPs associated with PON1
 - 3.4.2. Stereoselective hydrolysis commercial OPs pesticides by alloforms of PON1 Q192R
 - 3.4.3. PON1, an enzyme that stereoselectively hydrolyzes OP nerve agents
 - 3.4.4. PON1 recombinants and stereoselective hydrolysis of OP nerve agents
 - 3.5. The activity of PTEs in birds
4. Conclusions
5. Acknowledgments
6. References

1. ABSTRACT

Some organophosphorus compounds (OPs), which are used in the manufacturing of insecticides and nerve agents, are racemic mixtures with at least one chiral center with a phosphorus atom. Acute exposure of humans to these mixtures induces the covalent modification of acetylcholinesterase (AChE) and neuropathy target esterase (NTE) and causes a cholinergic syndrome or organophosphate-induced delayed polyneuropathy syndrome (OPIDP). These irreversible neurological effects are due to the stereoselective

interaction of the racemic OPs with these B-esterases (AChE and NTE) and such interactions have been studied *in vivo*, *ex vivo* and *in vitro*, using stereoselective hydrolysis by A-esterases or phosphotriesterases (PTEs) and the PTE from *Pseudomonas diminuta*, and paraoxonase-1 (PON1) from mammalian serum. PON1 has a limited hydrolytic potential of the racemic OPs, while the bacterial PTE exhibits a significant catalytic activity on the less toxic isomers P(+) of the nerve agents. Avian serum albumin also shows a hydrolyzing

capacity of chiral OPs with oxo and thio forms. There are ongoing environmental and bioremediation efforts to design and produce recombinants as bio-scavengers of OPs.

2. INTRODUCTION

2.1. Organophosphorus compounds (OPs) and their toxicity

OPs are amide esters or thiol derivatives of phosphoric acid or phosphorothioic acid; they have been synthesized since 1940. OPs have become the most used insecticides around the world because of their great ability to inhibit B-esterases (1, 2). The acute toxic effect of OPs on biological systems occurs through acetylcholinesterase (AChE) inhibition. Therefore, this cholinergic syndrome is caused by the acetylcholine accumulation in the peripheral synapsis (neuromuscular) and central synapsis (neuron-neuron) that primarily induce salivation, lacrimation, gastrointestinal stimulation, trembling, and convulsions. Abdominal respiratory paralysis is the main cause of human deaths caused by intoxication with these compounds. The cholinergic syndrome caused by OPs appears clinically during the first 72 h of the intoxication (3–5). In some cases of acute intoxication by OP racemic insecticides, such as phosphates, phosphonates, and phosphoramidates, irreversible and delayed symptoms with signs of ataxia appear between the second and third week after the exposure. This neurodegenerative syndrome is known as organophosphate-induced delayed polyneuropathy (OPIDP) (6, 7) and correlates with the inhibition and aging of the so-called neuropathy target esterase (NTE) of the central nervous system (8).

2.2. Metabolism and treatment of OP intoxication

The morbidity and mortality that occur in humans due to OP intoxication due to agricultural activities and the continuous threat of the use of nerve agents in wars have encouraged the search for enzymatic systems that can hydrolyze these compounds. This action would neutralize adverse effects to the human population. The current pharmacological treatment for cholinergic syndrome

consists of the administration of atropine (an ACh muscarinic antagonist) and oximes (reactivation of AChE), which have been ineffective in most of the severe acute intoxication cases (9–11). There is no drug of choice to OPIDP. Consequently, treatment involves the application of biomolecules that interact with OPs to protect human life. Therefore, the administration of human serum butyrylcholinesterase (HuBuChE) has been suggested. This B-esterase may represent a promising scavenger biomolecule for OP intoxication (12). However, its main limitation is its stoichiometry: A large quantity of the enzyme is required to achieve protection from OP intoxication *in vivo*. Some proposed second-generation bio-scavengers include A-esterases or phosphotriesterases (PTEs), such as bacterial PTEs, and, mainly, mammalian serum paraoxonase-1 (PON1). Notably, variant recombinant PON1s have increased the enzyme's specificity for more toxic OPs insecticides (13–15). These recombinant proteins could be a therapeutic alternative in the intoxication by racemic mixtures of these compounds.

2.3. Chiral OPs

Some OP pesticides have been commercialized as active ingredients in insecticides; the chemical structures have at least one chiral center in the pentavalent phosphorus atom (Figure 1). The biological activity of these racemic compounds is the result of the detoxification of one enantiomer. The other enantiomers can have adverse effects due to their interaction with target biomolecules (16–21). Johnson and coworkers (22) examined the stereoselectivity of cholinergic and delayed neurotoxicity with racemic OP mixtures. They evidenced stereoselective neurotoxicity of O-ethyl O-4-nitrophenyl phenylphosphonothioate (EPN) and methamidophos insecticides. Other commercial insecticides, such as ruelene, trichloronate, and fenamiphos, require biochemical studies with regard to their stereoselective interaction with B-esterases. Given that these insecticides represent an environmental risk for intoxication (19, 20, 23, 24), their differential toxicity among biological species and individuals may be due to the stereoselective hydrolysis of these racemic mixtures by A-esterases (16). The limited scientific information about stereoselective OP hydrolysis may be




Figure 1. Three-dimensional representation of the docked complex of chiral structure of organophosphorus pesticides; *denotes chiral center.

attributed to the reduced number of chiral separation methods and the lack of OP enantiomer standards. The separation and collection of enantiomers of some commercial chiral OPs with chiral liquid chromatography have allowed stereoselective toxicological evaluation (25–37). The enantiomer (–)-trichloronate is 8–11 times more toxic than (+)-trichloronate, and it contributed 68% and 72% of the harmful activity against the microorganisms *Ceriodaphnia dubia* and *Daphnia magna*, respectively. Profenophos and fonofos showed stereoselective toxicity for (–) enantiomers in *C. dubia* (92–94%) and *D. magna* (87–94%). However, the stereoselective toxicity of the chiral OPs is not exclusive to the (–) isomers, because the (+) enantiomers of fenamiphos and leptophos were 2.0–3.8 times more toxic to *D. magna* than the (–) isomers (38, 39). This selective poisonous effect for the (+) enantiomers has been observed for phosphoramidates such as methamidophos and acephate, which show 97% effectiveness against domestic flies versus their racemic mixtures (40).

3. STEREOSELECTIVE HYDROLYSIS

3.1. Stereoselective hydrolysis determines the toxicity of chiral compounds

Stereoselective hydrolysis of racemic OPs is defined as the preferential hydrolysis of one stereoisomer over the other (41). The enantiomers of

chiral OPs induce different toxic effects: Stereoselective hydrolysis is one of the biological factors that determines their toxicity. The adverse impact corresponds to the isomer that withstands *in vivo* hydrolysis by A-esterases or PTEs. The toxic relevance of degradation has been demonstrated for EPN (42), methamidophos (43, 44), and methamidophos analogs, specifically the S-methyl series and dichlorophenyl phosphoramidates (45–48). PTEs that hydrolyze chiral OPs have been identified in invertebrates, mammals, and—mainly—bacteria (49–57). PTEs are divalent metallic cation-dependent hydrolases (53, 58–60). The structure of these metalloproteins shows binding sites for hydrophobic OPs due to a three-pocket conformation that binds the leaving group and the other two substituent groups of the molecule to position the phosphorous center and perform the catalysis (58, 61–66). The crystalline structures of several bacterial PTE have been obtaining, and their catalytic capacities have been associated with structural folding, like TIM barrel, "pita-bread," β -lactamase, and β -propeller (61, 62, 67, 68). Paraoxon is considered to be a good substrate for PTEs, due to the catalytic efficiency: K_{cat} 104 s^{-1} and K_{cat}/K_m of approximately $108\text{ M}^{-1}\text{ s}^{-1}$ in the usual laboratory *in vitro* assay (59). However, PTEs can be considered nonspecific for OPs (69–76). In particular, bacterial PTEs are efficient enzymes for substrates with phenolic (77), thiol, and halogenide electron acceptors (72, 77). This broad substrate affinity for

these esterases is explained by the nonspecific nature of the substrate-binding site: There are three ester groups of the substrate interact with the three pockets hydrophobic site in the enzyme surface (78). The stereoselectivity of the wild-type PTE from *Pseudomonas diminuta* for chiral organic phosphates depends on the substituent bound to the central phosphorous atom (63, 71). Researchers confirmed the substrate specificity of this PTE with a library of 16 paraoxon analog compounds; the authors concluded that combinations of methyl, ethyl, isopropyl, and phenyl groups as structural substituents X and Y were substrates for this PTE, with values from 18000 s⁻¹ for dimethyl p-nitrophenyl phosphate to 220 s⁻¹ for diisopropyl p-nitrophenyl phosphate (79). The enzyme hydrolyzed the SP-enantiomer, preferably in the racemic mixtures of chiral OPs (80, 81). The stereoselectivity activity was evident for methyl isopropyl p-nitrophenyl phosphate; the hydrolysis of the SP enantiomer was 100 times higher than its corresponding RP enantiomer (79). The efficient hydrolysis of the EPN (81), acephate, and methamidophos insecticides (73), as well as other racemic mixtures of phosphate, phosphonate, and phosphinate esters, constitute examples of the stereoselective hydrolysis of PTEs. In some cases, this stereoselectivity is around five orders of magnitude higher compared with non-stereoselectivity (Table 1) (71).

Site-directed mutagenesis has allowed modification of the rate of catalytic hydrolysis, increasing or decreasing it, as well as the transformation of the PTE stereoselectivity of *P. diminuta* for OPs. Glycine (Gly) residues of the substrate hydrophobic union site to PTE play a crucial role in providing the stereoselectivity to these chiral compounds (82). The mutant protein G60A of PTE showed a 100-fold reduction in its Kcat/Km value for the RP enantiomer of methyl phenyl p-nitrophenyl phosphate. Consequently, the ratio of stereoselective hydrolysis increased 13000 times in favor of this enantiomer versus wild-type PTE (63, 79, 83). This same recombinant PTE protein rose from 1–3 orders of magnitude the stereoselectivity for other chiral phosphoric esters (71). Furthermore, mutant PTE I106G/F132G/H257Y reversed the stereoselectivity, because the RP enantiomer of 4-acetyl phenyl methyl phenyl phosphate was

hydrolyzed preferably (with a factor of 9.7×10^2). By contrast, the wild-type protein and mutant PTE G60A preferentially hydrolyzed the SP enantiomer (1.2×10^2 and 3.7×10^5 , respectively) (71).

3.2. Hydrolysis of nerve agents by PTEs

The most neurotoxic racemic OPs have been synthesized for use as agents of war; among the best known are sarin, soman, and VR (Figure 2). The adverse effects of these nerve agents depends on the stereochemistry in the phosphorous center (84). All contain a chiral center at the phosphorus atom, and some present a second chiral center in one carbon atom, such as soman. Bacterial PTEs hydrolyze most of the nerve agents in a stereoselective manner in favor of the RP isomers (85), which are less toxic for mammals. The detoxifying property of bacterial PTE on these warfare agents has been of great interest in medical toxicology and biotechnology for environmental bioremediation. Hoskin and coworkers (86) identified three enzymes in *Escherichia coli* that can hydrolyze soman, but only one of them showed stereoselectivity. The racemic mixture of soman was hydrolyzed with two-phase kinetic behavior: a fast initial phase and a subsequent slow phase, which approximates the observed non-enzymatic detoxification rate for soman. Hill and coworkers (87) demonstrated that organophosphorus acid anhydrolase (OPAA) from *Alteromonas* sp. hydrolyzed the isomer RPSC 7000 times more than the isomer SPSC from the soman analogs. The P(+) isomers of p-nitrophenyl sarin analogs were hydrolyzing by OPAA (2–4 fold) faster than bacterial wild-type PTE from *P. diminuta*, for chiral analogs of sarin and soman. the RP enantiomer of one sarin analog (Kcat = 2,600 s⁻¹) had a higher affinity compared with its corresponding SP enantiomer (Kcat = 290 s⁻¹). This stereoselectivity hydrolysis was reversed with the PTE mutant I106A/F132A/H254Y, with markedly reduced Kcat values: 410 s⁻¹ for the RP enantiomer (6 fold smaller) and 4200 s⁻¹ for the SP enantiomer (14 times greater) (88). Other similar enzymatic reactions were obtained for the hydrolysis of other chiral OPs with a thiolate leaving group. The comparison of the rates between soman and sarin analogs demonstrated that the pinacol substituent has less affinity than the isopropyl group in the active

Table 1. Hydrolysis of chiral OPs insecticides and nervous agent by PTEs

Chiral OP compound	Bacterial phosphotriesterase	Stereoselectivity (Fold)	References
Acephate	PTE from <i>E. coli</i> (wild-type)	S _P > R _P (100)	73
Methamidophos	PTE from <i>E. coli</i> (wild-type)	S _P > R _P (100)	73
EPN	PTE from <i>P. diminuta</i> (wild-type)	S _P > R _P	81
Paraoxon analogue	PTE from <i>P. diminuta</i> (wild-type)	S _P > R _P (100)	79
Sarin analogue	PTE from <i>P. diminuta</i> (wild-type)	R _P > S _P (9)	88
Sarin analogue	PTE from <i>P. diminuta</i> (I106A/F132A/H254Y mutant)	S _P > R _P (10)	88
Sarin analogue	PTE from <i>P. diminuta</i> (G60A mutant)	R _P > S _P (50)	88
Soman analogue	PTE from <i>P. diminuta</i> (wild-type)	R _P R _C > R _P S _C , S _P R _C , S _P S _C (10-1200)	88
Soman analogue	PTE from <i>P. diminuta</i> (I106A/F132A/H254Y mutant)	S _P R _C > S _P S _C , R _P R _C , R _P S _C , (5-37)	
Soman analogue	PTE from <i>P. diminuta</i> (G60A mutant)	R _P R _C > R _P S _C , S _P R _C , S _P S _C (4-6000)	88
Acetylphenyl methyl phenyl phosphate	PTE from <i>P. diminuta</i> (wild-type)	S _P > R _P (1.2 x 10 ²)	71
Acetylphenyl methyl phenyl phosphate	PTE from <i>P. diminuta</i> (G60A mutant)	S _P > R _P (3.7 x 10 ⁵)	71
Acetylphenyl methyl phenyl phosphate	PTE from <i>P. diminuta</i> (I106G/F132G/H257Y mutant)	R _P > S _P (9.7 x 10 ²)	71
Sarin analogue	OPAA from <i>Alteromonas</i> sp. (wild-type)	R _P > S _P (2)	86
Soman analogue	OPAA from <i>Alteromonas</i> sp. (wild-type)	R _P S _C > R _P R _C , S _P R _C , S _P S _C (29-7260)	86
Cyclosarin	PTE from <i>P. diminuta</i> (wild-type)	(+)GF > (-)GF (21)	89
Cyclosarin	OPAA from <i>Alteromonas</i> sp. (wild-type)	(+)GF > (-)GF (12)	89
Cyclosarin	OPAA from <i>A. haloplanktis</i> (wild-type)	(+)GF > (-)GF (24)	89
Cyclosarin	PTE from <i>P. diminuta</i> (H254G/H259W/L303T mutant)	(-)GF > (+)GF	89
VX nerve agent	PTE from <i>P. diminuta</i> (wild-type)	S _P = R _P (1)	91
VX nerve agent	PTE from <i>P. diminuta</i> (H254Q/H257F mutant)	S _P > R _P (12)	91
VX nerve agent	PTE from <i>P. diminuta</i> (L7ep-2b mutant)	R _P > S _P (12)	91
VR nerve agent analogue	PTE from <i>P. diminuta</i> (wild-type)	R _P < S _P (25)	85
VR nerve agent analogue	PTE from <i>P. diminuta</i> (G60A mutant)	R _P > S _P (7600)	85
VR nerve agent analogue	PTE from <i>P. diminuta</i> (I106A/F132A/H257Y mutant)	S _P > R _P (270)	85

Abbreviations: OP: Organophosphorus compound, PTE: Phosphotriesterase, EPN: O-ethyl O-4-nitrophenyl phenylphosphonothioate, OPAA: Organophosphorus acid anhydrolase, S_P: S_P-enantiomer, R_P: R_P-enantiomer, R_PR_C: R_PR_C-enantiomer, R_PS_C: R_PS_C-enantiomer, >, S_PR_C: S_PR_C-enantiomer, S_PS_C: S_PS_C-enantiomer, (+)GF: (+)GF-enantiomer, (-)GF: (-)GF-enantiomer.

site of the PTE enzyme wild-type of *P. diminuta*, because the sarin RP isomer is hydrolyzed faster (by two orders of magnitude) than the soman RPRC isomer (Table 1).

Harvey and coworkers (89) confirmed the stereoselective hydrolysis property of PTEs from *P.*

diminuta and *Alteromonas* sp., as well as OPAA from *Alteromonas haloplanktis*. Specifically, those wild-type proteins showed a hydrolysis ratio of 21.5, 12 and 24, respectively, in favor of the (+) isomer of cyclosarin. The H254G/H259W/L303T mutant reversed the stereospecificity of the native PTEs because it preferentially catalyzed the hydrolysis of




Figure 2. Three-dimensional representation of the docked complex of chemical structure of toxic OP nerve agents; *denotes chiral center.

the (–) isomer of cyclosarin ((+)/(–) ratio = 0.16), which is two times more toxic to AChE than the racemic compound. Tsai *et al.* (85, 90) have demonstrated that the inherent stereoselectivity of wild-type PTE from *P. diminuta* on the enantiomers RP of sarin, soman, and cyclosarin increased with the size of substituent group bound directly to phosphorous atom. The mutants of this wild-type protein have an increased stereoselective capacity for the *R/S* ratio (K_{cat}/K_m) from 22 to 760 times for a cyclosarin analog. In other cases, the PTE mutants reversed the stereoselectivity. In particular, the substitution of alanine with a glycine residue (mutant G60A) in the small pocket of this bacterial PTE improved the stereochemical preference with an *R/S* ratio (K_{cat}/K_m) from 25 to 7600 times in VR compound analog. The PTE I106A/F132A/H257Y mutant showed a stereoselective reversion for sarin, soman, cyclosarin, VX, and VR. Those mutant proteins showed levels of enzymatic activity up to 15,000 times greater for the SP isomers compared with wild-type PTE. The results are relevant from a toxicological perspective because they are the enantiomers that show the highest toxic potency for mammals.

3.2.1. Hydrolysis of V-type agents

The catalytic activity of the wild-type PTE bacterial (from *P. diminuta* and *Flavobacterium* sp.) toward V-type nerve agents is approximately three orders of magnitude lower than G-type nerve agents ($K_{cat}/K_m < 103 \text{ M}^{-1} \text{ s}^{-1}$) (75, 76). Tsai and coworkers (85) observed that wild-type PTE showed a slight hydrolysis preference for the SP enantiomer of VX (*S/R* ratio, $K_{cat}/K_m = 2$). Nevertheless, Bigley and

coworkers (91) did not observe stereoselective hydrolysis when they used the bacterial wild-type enzyme. However, the double mutant of bacterial PTE QF (H254Q/H257F) hydrolyzed the more toxic SP enantiomer 12 times more than the RP enantiomer of VX. This result is similar to the one obtained by Tsai and coworkers (85) with a VX analog. These authors also observed stereoselective catalysis: Hydrolysis of the RP isomer (reverse hydrolysis) was 12 times higher than its corresponding SP enantiomer with the mutant L7ep-2b (CVQFL + H254R/N265D/A270D/L272M/S276T) (91). Studies of PTE from *P. diminuta* have suggested their potential role as a therapeutic intervention for nerve agent intoxication to attenuate the neurological deficit in humans who are chronically exposed due to wars. With this objective, mutant PTEs have been designed to provide stereoselectivity on the more toxic isomer (91).

3.3. PON1, a protein restricted in its ability to hydrolyze chiral OPs

Serum arylalkylphosphatase (EC 3.1.8.1.), also known as PON1, is the best-known protein of the family of enzymes called paraoxonases from mammalian tissues (mainly liver and human serum). Its name is derived from its capacity to hydrolyze paraoxon, which is a metabolite of the neurotoxic insecticide parathion (92); in addition, it was the first of the three PON members discovered. Molecular studies have revealed that PON1 messenger RNA (mRNA) is widely distributed in the brain, kidney, liver, small intestine, and lungs of animals. Nevertheless, PON1 only reaches significant levels of toxicological interest in the liver and serum (93–97). PON1 is a calcium-dependent A-esterase that comprises 354 amino acids; its molecular weight is 45 kDa (95, 96, 98–100). It is synthesized in the liver (98) and secreted into the bloodstream to bind high-density lipoprotein (HDL) (101). PON1 is an A-esterase with paraoxonase, arylesterase, and lactonase activity. Phenylacetate is one substrate for which PON1 has high affinity (102, 103). Since its identification in animal tissues, researchers have proposed that PON1 is involved in protection against OP toxicity (104–107). *In vitro* studies have demonstrated that PON1 hydrolyzes toxic aryl esters and OP insecticides (in the oxo

form), such as parathion, chlorpyrifos, diazinon, and chiral nerve agents, including sarin and soman (108–110). Despite the broad affinity for ester substrates, PON1 shows different catalytic hydrolysis rates that depend on the chemical's structural conformation (108, 110, 111). PON1 is considered to be a relevant protein for *in vivo* OP detoxification because species like birds and fish, which have low serum PON1 activity, are very susceptible to OP insecticide intoxication (112). By contrast, species with greater levels of this protein, such as mammals, are more resistant to the toxicity of these compounds (108, 113, 114). The most direct evidence of the protective role of PON1 against OP toxicity has been demonstrated in rodent models. The exogenous administration of purified PON1 protected against the toxicity of OPs in the oxo form. The extension of this protective effect was dependent on the efficiency catalytic of PON1 versus OP (115–118). The catalysis rate of human serum PON1 (HuPON1) on chiral nerve agents has been considered low in toxicological terms. Therefore, PON1 might be a PTE with limited protection against OP toxicity because it only hydrolyzed a few OPs and it is unable to act on racemic mixtures. For this reason, protein engineering has been applied to this A-esterase to increase specificity and rate of catalytic hydrolysis for OPs, including racemic warfare agents and chiral insecticides.

The relatively low expression of A-esterases, like PON1, during neurodevelopment increases the susceptibility to OP pesticide toxicity in human populations (119, 120). The high toxicity of OP insecticides correlates with PON1 levels and carboxylesterases related to age (120, 121). Experiments with rodents have demonstrated that the ontogeny of this esterase correlates with the toxicity of these compounds (119–121). Specifically, clinical studies have shown that newborn children have one third to one quarter of the PON1 serum levels that are found in adults (122–124), as well as variability in the active protein levels among individuals (125). The combination of genetic variability and PON1 expression in human development can mean up to 160-fold greater susceptibility to OPs (123). A longitudinal epidemiological study concluded that PON1 activity in children increased 3.5 times from birth to 7 years.

Nevertheless, these PON1 levels at the age of 7 years were significantly lower (1.8%) than the maternal levels, and the difference was more evident for mothers and children with genotypes (QQ) associated with one PON1 copy with low activity (see section 3.4.2.) (124). In a longitudinal study of the cohort, González and coworkers (126) found that the PON1 levels in the serum of 9-year-old children were lower (1.7–7.9%) than the levels in their respective mothers. However, these differences were not statistically significant; hence, PON1 levels in children at this age may reach the levels found in adults.

3.4. Toxicity and stereoselective hydrolysis of OPs in animal tissues

Chiral OPs induce adverse effects in the biological systems related to their stereochemical structure and the affinity to B-esterases from the nervous system (127). Johnson and coworkers (43) established that the administration of 5–7 times the median lethal dose (LD50) of D (+)-methamidophos induced OPIDP in hens. By contrast, the administration of L(–)-methamidophos at similar doses did not induce OPIDP (128). The ratios of rate constants for the inhibition of AChE/NTE for D (+)-methamidophos were 2 for hens and 3 for humans; the same ratios for L(–)-methamidophos were to 900 for hens and humans (129). This same group previously demonstrated that the enantiomers of one OP showed a different capacity to inhibit AChE and NTE in hen's brain, with consequent stereoselective OPIDP (22). These results suggested stereoselective hydrolysis when racemic mixtures of OPs that include phenyl phosphonothioates like EPN (130) and phosphoramidothioates like methamidophos and its analogs when administered *in vivo* (45, 131). Other pre-clinical studies on aquatic and cellular toxicity have corroborated the stereoselective toxicity of the chiral OPs pesticides (132).

Fenamiphos is widely using as a nematicide in the production of fruits, vegetables, grains, and tobacco, among other crops (133, 134). This racemic OP is highly toxic to aquatic and terrestrial organisms (135). Aquatic toxicity studies in *D. magna* have demonstrated that (+)-fenamiphos is 20 times more toxic than (–)-fenamiphos. This

stereospecific aquatic toxicity was corroborated with isomers of other chiral insecticides in *D. magna* and *C. dubia* (136), as well as in *ex vivo* inhibition studies of BuChE from horse serum (38) and AChE from PC12 rat cells (137). Notably, the racemic insecticide profenophos showed a stereoselective effect *in vitro* on AChE from animal serum, and (+)-profenophos inhibited this B-esterase up to 23 times more than (–)-profenophos. Nevertheless, *in vivo* studies have clearly shown that this isomer is approximately 23 times less potent as an inhibitor of AChE (138). The authors explained this contrary, adverse effect by suggesting a stereospecific bioactivation *in vivo* of enantiomer (–)-profenophos (139), as was observed for (–)-isofenphos in rat liver microsomes (140). Since the first reports of inhibition and aging *in vivo* and *in vitro* by chiral OPs of AChE and NTE esterases, it has been suggested that stereoselective metabolism (hydrolysis) should be considered in the neurotoxicity of these compounds. For this reason, the characterization of the hydrolyzing role of A-esterases or PTEs, including PON1 from human serum (HuPON1), on the chiral OPs, insecticides, and warfare agents, is relevant in terms of public health and environment protection (Table 2).

3.4.1. The calcium-dependent stereoselective activity of OPs associated with PON1

PON1 activity in rabbit serum was first identified with paraoxon as a substrate in the presence of calcium (141), so ethylenediaminetetraacetic acid (EDTA) can inhibit it. Currently, this activity in animal tissues, such as liver and serum, is defined as calcium-dependent and EDTA-sensitive PTE activity. Albumin is a vertebrate serum protein with paraoxonase activity; it hydrolyzes paraoxon in the absence of calcium in mammalian serum (142). Studies carried out with neuropathic phosphoramidates, like methamidophos and its analogs, were among the first performed on stereoselective hydrolysis of OPs. In particular, the incubation of racemic O-hexyl-S-methyl phosphoramidite (HXM) with rabbit serum confirmed a slow but specific elimination of the *R*-(+)-HXM enantiomer (143). The stereoselectivity of this catalytic reaction was evident with its compound analog, O-2,5-dichlorophenyl phosphoramidate

(HDCEP) in several animal tissues (144, 145). These *ex vivo* assays showed stereospecific calcium-dependent hydrolysis of *S*-(–)-HDCEP in the microsomal fraction of rabbit liver and mainly in rat and rabbit serum. The EDTA-resistant hydrolysis of HDCEP was not stereoselective in these tissues and animal species (145, 146). These results, suggest that the blood concentration of *R*-(+)-HDCEP will remain higher than *S*-(–)-HDCEP and induce the neurotoxic effects.

3.4.2. Stereoselective hydrolysis of commercial OP pesticides by alloforms of PON1 Q192R

Mammalian serum PON1 hydrolyzes calcium-dependent OPs in the glutamine/arginine polymorphism at position 192 (Q192R). The Q192R polymorphism affects the hydrolysis levels of some racemic OPs substrates (98, 110, 115, 147). In our laboratory, the stereoselective hydrolysis of fenamiphos and HDCEP by different PON1 Q192R alloforms from human serum has been characterized by chiral chromatographic methods (32, 37). The stereoselective hydrolysis has been quantified by measuring the residual concentration (μM) of each insecticide enantiomer, after a specified incubation time with 2.5 mM calcium or 5 mM EDTA at physiological pH and temperature. There were significant differences for the stereoselective hydrolysis of fenamiphos by the different PON1 Q192R alloforms from human serum (36). The average residual concentration (μM) of (+)-fenamiphos and (–)-fenamiphos for each one of the three PON1 Q192R alloforms from adults and children were in a range of 166–200 μM . The highest level of hydrolysis (12%) was not significant ($p > 0.05$, Student's *t*-test). The lack of significant hydrolysis for the fenamiphos enantiomers in human serum suggests that age may not influence the catalytic efficiency of PON1 Q192R alloforms for the hydrolysis of chiral insecticides *in vivo*. These results contradict those reported for sarin, which established a greater susceptibility to chiral OPs intoxication associated with the age and to PON1 Q192R alloforms from human serum (104, 121, 148, 149).

For HDCEP hydrolysis by human serum samples, after a 60-min incubation at physiological conditions three PON1 Q192R alloforms showed an

Table 2. Stereoselective hydrolysis of OPs insecticides and nerve agent by PON1 and animal tissues

Chiral OP compound	Protein source	Stereoselectivity (Fold)	References
IMP-pNP	Mammalian serum PON1 (wild type)	P(+) > P(-)	155
IMP-pNP	Mammalian serum PON1 (V346A mutant)	P(+) > P(-)	155
Ciclosarin	Mammalian serum PON1 (wild type)	P(+) > P(-)	155
Ciclosarin	Mammalian serum PON1 (V346A mutant)	P(+) > P(-)	155
Soman	Mammalian serum PON1 (wild type)	P(+)C(+), P(+)C(-) > P(-)C(+), P(-)C(-)	155
Soman	Mammalian serum PON1 (V346A mutant)	P(+)C(+), P(+)C(-) > P(-)C(+), P(-)C(-)	155
Soman	Guinea-pig skin	P(+)C(+), P(+)C(-) > P(-)C(+), P(-)C(-) (~11)	156
Soman	Mouse skin	P(+)C(+), P(+)C(-) > P(-)C(+), P(-)C(-) (~15)	156
Soman	Human skin	P(+)C(+), P(+)C(-) > P(-)C(+), P(-)C(-) (~34)	156
Soman	Rat liver (soluble fraction)	P(+)C(-), P(+)C(+) > P(-)C(+), P(-)C(-)	161
Soman	Human serum	P(+)C(+), P(+)C(-) > P(-)C(+), P(-)C(-) (~40)	162
Soman	HuPON1 (wild-type)	P(+)C(+), P(+)C(-) > P(-)C(+), P(-)C(-) (~3)	163
EMP-MeCyC	HuPON1 (wild-type and mutants)	P(+) > P(-)	164
VX and VR	rHuPON1 (recombinant)	P(+) > P(-)	165
HDCP	Rabbit serum	S(-) > R(+)	142
HDCP	Rabbit serum	S(-) > R(+) (8-10)	145
HDCP	Rat serum	S(-) > R(+) (5)	145
HDCP	Hen, rata or rabbit liver (particulate or soluble fraction)	S(-) > R(+) (2-12)	145
HDCP	Hen, rata or rabbit kidney (particulate or soluble fraction)	S(-) > R(+) (1-12)	145
HDCP	Human serum	S(-) > R(+) (2-3)	33
HXM	Rabbit serum	R(+) > S(-)	143
Trichloronate	Human serum	(+) = (-)	171
Fenamiphos	Human serum	(+) = (-)	36
Profenofos	Human serum	(+) = (-)	172
Abbreviations: OP: Organophosphorus compound, PON1: Paraoxonase-1, HuPON1: Human serum PON1, rHuPON1: Recombinant human PON1, IMP-pNP = O-isopropyl-O-(p-nitrophenyl) methyl phosphonate, VX= VX nerve agent, VR= VR nerve agent, HDCP= O-Hexyl, O-2,5-dichlorophenyl phosphoramidate, HXM= O-n-hexyl-S-methylphosphorothioamidate, P(+): P(+)-enantiomer, P(-): P(-)-enantiomer, P(+)C(+): P(+)C(+)-isomer, P(+)C(-): P(+)C(-)-isomer, P(-)C(+): P(-)C(+)-isomer, P(-)C(-): P(-)C(-)-isomer, EMP-MeCyC: methylphosphonic acid 3-cyano-4-methyl-2-oxo-2H-coumarin-7-yl ester ethyl ester, (-): (-)-isomer, (+): (+)-isomer.			

exclusive and significant stereospecific calcium-dependent hydrolysis of S(-)-HDCP. Indeed, the remaining concentrations of this isomer were lower than R-(+)-HDCP in 47 human adult serum samples that were diagnosed by the PON1 192 polymorphism (33). This stereoselective calcium-dependent S(-)-HDCP hydrolysis is inhibited with EDTA and is

independent of the PON1 Q192R alloform, which shows a tendency for greater hydrolysis compared with the RR alloform. This research reinforces that R-(+)-HDCP (the isomer that inhibits NTE and causes its aging) might be the enantiomer that induces delayed neuropathy caused by this chiral phosphoramidate. In summary, the insecticide

fenamiphos is not hydrolyzed by PON1 Q192R alloforms from human serum. These data reinforce the hypothesis that PON1 has an irrelevant detoxifying role for OPs *in vivo* because of the limited number of chiral OPs that it hydrolyzes. When it does hydrolyze compounds, it prefers the less-toxic enantiomers, as is in the case of HDCP.

3.4.3. PON1, an enzyme that stereoselectively hydrolyzes OP nerve agents

The stereospecific calcium-dependent hydrolysis of warfare agents by mammalian tissues has been studied for more than 50 years to determine the toxic properties of its isomers on human health. The first study reported by Augustinsson (150) identified stereoselective degradation of tabun by pig kidney tissue. Cristen (151, 152) observed the stereoselective hydrolysis of P(+) sarin in the plasma of several species, which included rats and humans. Subsequently, other researchers used chromatographic techniques and corroborated the stereoselective hydrolysis of soman in animal tissues (153, 154) that included the skin homogenates of the mouse, human, and guinea pig. Those results showed the hydrolysis of the less toxic isomer (C(+/-) P(+)) of this compound, with a speed constant of $0.127 \text{ min}^{-1} \text{ g}^{-1}$. The stereospecificity of PON1 on nerve agents has been studied to determine the toxic properties of their isomers. Wild-type PON1 and their recombinants have shown metal-dependent stereospecific hydrolysis for the less toxic soman isomers (89, 155). Different studies have demonstrated the stereospecific hydrolysis of soman in rats, guinea pigs, and marmots (153, 154). Van Dongen (156) examined the stereoselective hydrolysis of soman using skin homogenized from guinea pigs, mice, and humans; it hydrolyzed the less toxic isomer (C(+/-) P(+)) of soman, with a rate constant of $0.127 \text{ min}^{-1} \text{ g}^{-1} \text{ l}^{-1}$. In 1957, Augustinsson reported that phosphorylphosphatase from pig liver had a stereospecific effect toward D-tabun. While, Cristen and coworkers (152) demonstrated the stereoselective hydrolysis of sarin in serum from several species; they also reported higher hydrolysis of P(+)-sarin than its corresponding P(-)-isomer (151). Later, researchers demonstrated

that the P(+)-sarin isomer was rapidly hydrolyzed (157, 158). On the other hand, Herbert and coworkers (159) showed stereoselectivity in fraction IV of human serum towards soman C+P+ isomer. Likewise, Benschop *et al.* (158) and De Jong and coworkers (160) reported that the tissues with a high PON1 content, such as mammalian serum and liver, preferably hydrolyzed the C(±) P(+) soman stereoisomers. These results for stereoselectivity were corroborated with a variant of the gen-shuffled (LR1) of HuPON1, expressed in bacteria, which exhibited stereoselective hydrolysis *in vitro* for the less toxic isomers soman and cyclosarin. Although the catalytic efficiency of HuPON1 against warfare agents, like sarin, VX, and soman, was low, its capacity to hydrolyze these toxic nerve agents *in vivo* makes it an attractive protein as a biological scavenger of chiral OPs (155). Meanwhile, Little and coworkers (161) reported significant non-stereoselective hydrolysis of the four soman isomers in the rat liver, data that suggest the presence of a 40-kDa enzyme that is not PON1. The stereoselective hydrolysis capacity of PON1 on chiral OP esters has been demonstrated against racemic substrates, like the sarin analog known as O-isopropyl-O-(p-nitrophenyl) methyl phosphonate (IMP-pNP). Amitai (155), showed the stereoselective hydrolysis of cyclosarin, soman, and O-(isopropyl)-O-(p-nitrophenyl)methyl phosphonate (IMP-PNP); these data corroborate that PON1 is less active toward the less toxic isomers.

De Bisschop (162) identified the stereoselective hydrolysis of soman in human serum. Yeung and coworkers (163) characterized the catalytic activity of HuPON1 toward each of the four soman isomers simultaneously by chiral-gas chromatography coupled to mass spectrometry. The K_{cat}/K_m values ranged from 625 to $4130 \text{ mM}^{-1} \text{ min}^{-1}$, with the following order for the isomers: C(+) P(+) > C(-) P(+) > C(+) P(-) > C(-) P(-). These data indicate that the soman hydrolysis by HuPON1 is stereoselective. Wild-type HuPON1 showed low activity, but its catalytic hydrolysis of the four soman stereoisomers was stereospecific. A critical assumption in the analytical model developed to determine the kinetic constant for each stereoisomer

is that each one behaves as an independent substrate, but competitive in the hydrolysis reaction.

3.4.4. PON1 recombinants and stereoselective hydrolysis of OP nerve agents

The reversal of stereoselective hydrolysis through recombinant mammalian PON1 has been developing by Amitai and coworkers from the Israel Institute for Biological Research. They have proposed that research should aim to increase enzymatic detoxification toward the more toxic P(–) isomer of nerve agents because wild-type mammalian PON1 have shown calcium-dependent stereoselective hydrolysis toward the less toxic P(+) enantiomers of those neurotoxic compounds. Previous studies on OP hydrolysis with recombinant PON1 have allowed the identification of Leu69, Val346, and His115 of PON1 as key positions that enhance the hydrolysis of cyclosarin, soman, and other nerve agents. However, residual AChE inhibition studies have suggested their stereoselective hydrolysis toward the less toxic P(+) isomer of these chiral OPs similar to the stereoselectivity of wild-type PON1. For these studies, the authors designed and synthesized other PON1 variants as well as new asymmetric fluorogenic OPs analogs of VX, cyclosarin, and soman. Finally, they demonstrated through AChE inhibition assay that the recombinant HuPON1 L69V/S138L/S193P/N287D/V346A showed reverse stereoselectivity toward the more toxic P(–) isomer of an analog compound of these warfare agents (164).

On the other hand, Otto and coworkers in 2010 (165) demonstrated the stereoselective hydrolysis of P(+) enantiomer of VX and VR by HuPON1 purified from *Trichoplusia ni* larvae. This HuPON1 variant was resistant to the hydrolysis of non-chiral insecticides, such as chlorpyrifos. The P(+) isomer of VX was fully hydrolyzed after 240 min, but its corresponding P(–) isomer was not hydrolyzed after 360 min. The stereoselectivity of the VR racemic mixture was similar to the observed for VX; the P(+) isomer was fully hydrolyzed after 420 min. The preferential hydrolysis of rHuPON1 on one particular isomer is indicative of the conformational restrictions of the active site of PON1 variant, where the fixation and catalysis are dependent on the three-

dimensional arrangement of substituents O-alkyl around chiral phosphor atom in OPs. The lack of hydrolysis toward P(–) isomers of VX or VR by rHuPON1 might result from the enzyme's inability to bind the substrate, a phenomenon that inhibits the catalysis. Kirbli and coworkers (166) synthesized recombinant single (H115W) and double (H115W/F347W) PON1s to generate variants that hydrolyzed class G and V warfare agents. They reported that H115W PON1 recombinant increased the catalytic activity levels of chiral OPs to wild-type PON1 protein. The double variant H115W/F347W PON1 showed a light stereoselective hydrolysis toward the tabun P(–) isomer ((–)/(+) ratio = 1.34) versus simple mutant H115W PON1 ((–)/(+) ratio = 1.06). These results suggest the participation of the amino acid tryptophan at position 347 near the active site residues promotes higher affinity binding of the P(–) isomer compared with the P(+) isomer. Goldsmith and coworkers (167) have used direct evolution to increase PON1 activity toward the more toxic S_P isomer of nerve agents G-type (tabun, sarin, soman, and cyclosarin). The PON1 variants showed a ≤ 340 increase in the ratios and catalytic efficiencies of $0.2\text{--}5 \times 10^7 \text{ M}^{-1} \text{ min}^{-1}$. Additionally, there was PON1 stereospecificity reversal, from an enantiomeric ratio of $(E) < 6.3 \times 10^{-4}$, in favor of the RP isomer of the cyclosarin analog and wild-type PON1, to $E > 2,500$ for the S_P isomer in an evolved variant. PON1 variants can hydrolyze the toxic S_P isomer of cyclosarin ($\leq 1.75 \times 10^7 \text{ M}^{-1} \text{ min}^{-1}$) efficiently. This result had been previously obtained using directed evolution (168).

3.5. The activity of PTEs in birds

Research has identified a phosphotriesterase activity that is different from PON1 in birds. This activity is not calcium-dependent and EDTA-resistant in hen serum; this activity was named HDCPase due to the ability to hydrolyze HDCP. Sogorb and coworkers (169) identified albumin as the protein responsible for this PTE activity. Subsequently, *ex vivo* experiments with particulate fraction of the hen, rabbit, and rat liver, as well as serum from rabbit and rat, demonstrated the stereoselective activity of S(–)-HDCP (146), which was in a range of 1–3 fold greater when the microsomal fraction of the liver was used in the assay

(10–80 mg) (147). Toxicological research has demonstrated that employing high concentrations of subcellular fractions for *in vitro* or *ex vivo* tests achieved a more realistic approximation of the stereoselective hydrolytic processes of OPs in biologic systems *in vivo*. Our research group recently identified novel PTE activity in chicken (34) and turkey serum (37). It is 20 fold higher than calcium-dependent HDCP activity, which is copper-dependent and stereoselective to the enantiomers of higher toxicity of HDCP and trichloronate; *R*-(+)-HDCP and (–)-trichloronate (a chiral compound in thio form), respectively. This new A-esterase activity has been identifying in chicken and turkey serum albumins (35, 170).

4. CONCLUSIONS

The results of studies on stereoselective hydrolysis by bacterial wild-type PTEs and their recombinants on chiral warfare agents have allowed researchers to suggest potential uses in the clinical toxicology treatment against racemic OPs toxics. In the field of biotechnology, these proteins can be used in the elaboration of bioreactors in environmental bioremediation. Human serum PON1 is a PTE with a limited role in OP hydrolysis because it only hydrolyzes a few non-chiral OP insecticides. Indeed, the main limitation comes from the limited hydrolysis of chiral OP insecticides, or its preference for hydrolyzing the isomers with low toxicity. Biotechnological production of recombinant PTEs with stereoselective hydrolysis of OPs is required in the field of the clinic and veterinary toxicology for the treatment of intoxications caused by chiral OP insecticides. Finally, the toxicological field needs to continue in the discovery and design of new A-esterases or PTE proteins that hydrolyze chiral OPs compounds or their neurotoxic enantiomers.

5. ACKNOWLEDGMENTS

This manuscript has been supported by project SEP/CONACYT 257092.

6. REFERENCES

1. M. Johnson: Organophosphates and delayed neuropathy – Is NTE alive and

well? *Toxicol Appl Pharmacol* 102, 385–399 (1990)

2. WY. Hou, D.X. Long, H.P. Wang, Q. Wang, and Y.J. Wu: The homeostasis of phosphatidylcholine and lysophosphatidylcholine was not disrupted during tri-o-cresyl phosphate-induced delayed neurotoxicity in hens. *Toxicology* 252, 56–63 (2008)
DOI: 10.1016/j.tox.2008.07.061
3. T.R. Fukuto: Mechanism of action of organophosphorus and carbamate insecticides. *Environ Health Perspect* 87, 245–254 (1990)
DOI: 10.1289/ehp.9087245
4. T.C. Marrs: Organophosphate poisoning. *Pharmacol Therapeut* 58(1), 51-66 (1993)
DOI: 10.1016/0163-7258(93)90066-m
5. P. Taylor. Anticholinesterase agents. In: Gilman AG and Goodman LS (eds), *The Pharmacological Basis of Therapeutics*. New York: Macmillan Publishing Co. Inc, 110-28 (1985)
6. R.M. Salvi, D.R. Lara, E.S. Ghisolfi, L.V. Portela, R.D. Dias, and D.O. Souza: Neuropsychiatric evaluation in subjects chronically exposed to organophosphate pesticides. *Toxicol Sci* 72, 267–271 (2003)
DOI: 10.1093/toxsci/kfg034
7. S.J. Wijeyesakere, R.J. Richardson. Neuropathy target esterase. R. Krieger (Ed.), *Hayes' Handbook of Pesticide Toxicology* (3rd ed.), Academic Press, San Diego, 1435–1455 (2010)
8. M.K. Johnson. The delayed neurotoxic effect of some organophosphorus compounds. Identification of the

- phosphorylation site as an esterase. *Biochem J* 114, 711-717 (1969).
DOI: 10.1042/bj1140711
9. R.M. Dawson: Review of oximes available for treatment of nerve agent poisoning. *J Appl Toxicol* 14, 317-331 (1994)
DOI: 10.1002/jat.2550140502
10. T.M. Shih, T.C. Rowland, J. H. McDonough: Anticonvulsants for nerve agent induced seizures: The influence of the therapeutic dose of atropine. *J Pharmacol Exp Ther* 320, 154-161 (2007)
DOI: 10.1124/jpet.106.111252
11. B. Kadriu, A. Guidotti, E. Costa, J. Auta: Imidazenil, a non-sedating anticonvulsant benzodiazepine, is more potent than diazepam in protecting against DFP-induced seizures and neuronal damage. *Toxicology* 256, 164-174 (2009)
DOI: 10.1016/j.tox.2008.11.021
12. A. Saxena, W. Sun, C. Luo, T.M. Myers, I. Koplovitz, D.E. Lenz, B.P. Doctor: Bioscavenger for protection from toxicity of organophosphorus compounds. *J Mol Neurosci* 30, 145-148 (2006)
DOI: 10.1385/jmn:30:1:145
13. D.E. Lenz, D. Yeung, J.R. Smith, R.E. Sweeney, L.A. Lumley, D.M. Cerasoli: Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. *Toxicology* 20, 233(1-3):31-9 (2007)
DOI: 10.1016/j.tox.2006.11.066
14. D. Rochu, E. Chabrière, P. Masson: Human paraoxonase: A promising approach for pre-treatment and therapy of organophosphorus poisoning. *Toxicology* 233(1-3), 47-59 (2007)
DOI: 10.1016/j.tox.2006.08.037
15. R.C. Stevens, S.M. Suzuki, T.B. Cole, S.S. Park, R.J. Richter, C.E. Furlong: Engineered recombinant human paraoxonase 1 (rHuPON1) purified from *Escherichia coli* protects against organophosphate poisoning. *Proc Natl Acad Sci U S A* 105(35), 12780-4 (2008)
DOI: 10.1073/pnas.0805865105
16. M.G. Nillos, J. Gan, D. Schlenk: Chirality of organophosphorus pesticides: Analysis and toxicity. *J Chromatogr B* 878, 1277-1284 (2010)
DOI: 10.1016/j.jchromb.2009.11.022
17. A. Williams: Opportunities for chiral agrochemicals. *Pestic. Sci* 46(1), 3 (1996)
DOI: 10.1002/(SICI)1096-9063(199601)46:1<3::AID-PS337>3.0.CO;2-J
18. M. Sasaki. In: Chirality in Agrochemicals, N. Kurihara, J. Miyamoto(Eds.).Wiley, Chichester, England, 85 (1998)
19. A.W. Garrison: Probing the enantioselectivity of chiral pesticides. *Environ. Sci. Technol* 40, 16-23 (2006)
DOI: 10.1021/es063022f
20. C. Wong: Environmental fate processes and biochemical transformations of chiral emerging organic pollutants. *Anal Bioanal Chem* 386, 544-58 (2006)
DOI: 10.1007/s00216-006-0424-3
21. E.M. Ulrich: Pesticide exposure and chiral chemistry: The pyrethroid family. *Chimica oggi (chemistry today). Teknoscienze, Milano, Italy* 25(5), 37-39 (2007)

22. M.K. Johnson, D.J. Read: The effect of steric factors on the interaction of some phenyl phosphonates with acetylcholinesterase and neuropathy target esterase of hen brain. *Pestic Biochem Physiol* 25, 133–142 (1986)
DOI: 10.1016/0048-3575(86)90040-4
23. H. Anigbogu, A.W. Woldeab, J.K. Garrison: Avants, Enantioseparation of Malathion, Crufomate, and Fensulfothion Organophosphorus Pesticides by Mixed-Mode Electrokinetic Capillary Chromatography. *Int. J. Environ. Anal. Chem* 83, 89–100 (2003)
DOI: 10.1080/0306731021000048018
24. H. Huhnerfuss, M.R. Shah: Enantioselective chromatography – a powerful tool for the discrimination of biotic and abiotic transformation processes of chiral environmental pollutants. *J Chromatogr A* 1216(3), 481–502 (2009)
DOI: 10.1016/j.chroma.2008.09.043
25. T.D. Doyle, W.M. Adams, F.S. Fry, and I.W. Wainer: The application of HPLC chiral stationary phases to stereochemical problems of pharmaceutical interest: A general method for the resolution of enantiomeric amine as β -naphthylcarbamate derivatives. *J. Liq. Chromatogr* 9, 455–471 (1986)
DOI: 10.1080/01483918608076647
26. K.J. Duff, H.L. Gray, R.J. Gray, and C.C. Bahler: Chiral stationary phases in concert with homologous chiral mobile phase additives: Push/pull model. *Chirality* 5, 201–206 (1993)
DOI: 10.1002/chir.530050402
27. S.J. Grieb, S.A. Matlin, J.G. Philips, A.M. Belenguer, H.J. Ritchie: Chiral HPLC with carbohydrate carbamates influence of support structure on enantioselectivity. *Chirality* 6, 129–134 (1994)
DOI: 10.1002/chir.530060213
28. Y. Okamoto, K. Hatada: Resolution of enantiomers by HPLC on optically active poly (triphenylmethyl methacrylate). *J Liq Chromatogr* 9, 369–384 (1986)
DOI: 10.1080/01483918608076642
29. Y. Okamoto, Y. Kaida: Resolution by high-performance liquid chromatography using polysaccharide carbamates and benzoates as chiral stationary phase. *J Chromatogr A* 666, 403–419 (1994)
DOI: 10.1016/0021-9673(94)80400-1
30. M.G. Williams, W.Z. Zhong: Stereospecific determination of HIV aspartyl protease inhibitor, PNU-103017, in rat, dog and human plasma using a Pirkle-concept high-performance liquid chromatographic column. *J Chromatogr B* 694, 169–177 (1997)
DOI: 10.1016/s0378-4347(97)00121-7
31. T. Zhang, E. Francotte: Chromatographic properties of composite chiral stationary phases based on cellulose derivatives. *Chirality* 7, 425–433 (1995)
DOI: 10.1002/chir.530070607
32. J.J. Ellington, J.J. Evans, K.B. Prickett, W.L. Champion: High performance liquid chromatographic separation of the enantiómeros of organophosphorus pesticides on polysaccharide chiral stationary phases. *J Chromatogr* 928 (2), 145–154 (2001)
DOI: 10.1016/s0021-9673(01)01138-4
33. A. Monroy-Noyola, B. Trujillo, P. Yescas, F. Martínez-Salazar, S. García-Jiménez, C. Ríos, E. Vilanova: Stereospecific hydrolysis of a phosphoramidate used as

- an OPIDP model by human sera with PON1 192 alloforms. *Arch. Toxicol* 89, 1801-1809 (2015)
DOI: 10.1007/s00204-014-1327-2
34. A. Monroy-Noyola, M.A. Sogorb, N. Díaz-Alejo, E. Vilanova: Copper activation of organophosphorus compounds detoxication by chicken serum. *Food Chem. Toxicol* 106, 417-423 (2017)
DOI: 10.1016/j.fct.2017.05.055
35. A. Monroy-Noyola, M.A. Sogorb, E. Vilanova: Albumin, the responsible protein of the Cu²⁺-dependent hydrolysis of O-hexyl O-2,5-dichlorophenyl phosphoramidate (HDGP) by chicken serum "antagonistic stereoselectivity". *Food Chem Toxicol* 120, 523-527 (2018)
DOI: 10.1016/j.fct.2018.07.047
36. D. Almenares-Lopez, M.F. Martínez-Salazar, M.L. Ortiz-Hernandez, R. Vazquez-Duhalt, A. Monroy-Noyola: Fenamiphos is recalcitrant to the hydrolysis by alloforms PON1 Q192R of human serum. *Toxicol in vitro* 27(2), 681-5 (2012)
DOI: 10.1016/j.tiv.2012.11.014
37. D. Almenares-Lopez, A. Juantorena, K. Rosales, E. Vilanova, C Ríos, A. Monroy-Noyola: Copper-dependent hydrolysis of trichloronate by turkey serum studied with use of new analytical procedure based on application of chiral chromatography and UV/Vis spectrophotometry. *J Chromatogr B* 1105, 203–209 (2019)
DOI: 10.1016/j.jchromb.2018.12.026
38. Y.S. Wang, K.T. Tai, J.H. Yen: Separation, bioactivity, and dissipation of enantiomers of the organophosphorus insecticide fenamiphos. *Ecotoxicol Environ Saf* 573, 46–353 (2004)
DOI: 10.1016/j.ecoenv.2003.08.012
39. J.H. Yen, C.C. Tsai, Y.S. Wang: Separation and toxicity of enantiomers of organophosphorus insecticide leptophos. *Ecotoxicol Environ Saf* 55, 236–242 (2003)
DOI: 10.1016/s0147-6513(02)00066-0
40. A. Miyazaki.; T. Nakamura, M. Kawaradani, S. Maruno: Resolution and biological activity of both enantiomers of methamidophos and acephate. *J Agric Food Chem* 28, 1591-1597 (1988)
DOI: 10.1021/jf00082a042
41. E. Vilanova, M.A. Sogorb: The role of phosphotriesterase in the detoxication of organophosphorous compound. *Crit Rev Toxicol* 29(1), 21-57 (1999)
DOI: 10.1080/10408449991349177
42. H. Ohkawa, N. Mikami, Y. Okuno, J. Miyamoto: Stereospecificity in toxicity of the optical isomers of EPN. *Bull Environ Contam Toxicol* 18(5), 534-40 (1977)
DOI: 10.1007/BF01683998
43. M.K. Johnson, E. Vilanova, D.J. Read: Anomalous biochemical responses in tests of the delayed neuropathic potential of methamidophos (O, S Dimethyl phosphorothioamidate), its resolved isomers and of some higher O alkyl homologues. *Arch Toxicol* 65, 618-624 (1991)
DOI: 10.1007/BF02098026
44. G.L. Emerick, G.H. DeOliveira, R.V. Oliveira, M. Ehrich: Comparative *in vitro* study of the inhibition of human and hen esterases by methamidophos enantiomers. *Toxicology* 292(2-3), 145-50 (2012)
DOI: 10.1016/j.tox.2011.12.004
45. E. Vilanova, M.K. Johnson, J.L. Vicedo: Interaction of some unsustituted

- phosphoramidate analogs of methamidophos (O, S dimethyl phosphorothioamidate) with acetylcholinesterase and neuropathy target esterase of hen brain. *Pest. Biochem Physiol* 28, 224-238 (1987)
DOI: 10.1016/0048-3575(87)90021-6
46. E. Vilanova, J.L. Vicedo: Serum cholinesterase inhibitors in the commercial hexane impurities. *Arch Toxicol* 53, 59-69 (1983)
DOI: 10.1007/BF01460002
47. M.A. Sogorb, N. Díaz-Alejo, M.C. Pellín, E. Vilanova: Inhibition and aging of neuropathy target esterase by the stereoisomers of a phosphoramidate related to methamidophos. *Toxicol Lett* 93, 95-102 (1997)
DOI: 10.1016/S0378-4274(97)00084-2
48. N. Diaz-Alejo, M.A.Sogorb, J.L.Vicedo, E. Vilanova.). A stereospecific phosphotriesterase in hen liver and brain. *Chem Biol Interactions* 108,187-196 (1998)
DOI: 10.1016/S0009-2797(97)00106-3
49. L.L. Harper, C.S. McDaniel, C.E. Miller, J.R. Wild: Dissimilar plasmids isolated from *Pseudomonas diminuta* MG and a *Flavobacterium* sp. (ATCC 27551) contain identical opd genes. *Appl. Environ. Microbiol* 54, 2586-2589 (1988)
50. L. Sun, Y. Dong, Y. Zhou, M. Yang, C. Zhang, Z. Rao, X. Zhang: Crystalization and preliminary X-ray studies of methyl parathion hydrolase from *Pseudomonas* sp. WBC-3. *Acta Crystallogr D Biol Crystallogr* 60, 954-956 (2004)
DOI: 10.1107/S09074444904005669
51. C. Zhongli, L. Shunpeng, F. Guoping: Isolation of methyl parathion-degrading strain M6 and cloning of the methyl parathion hydrolase gene. *Appl Environ Microbiol* 67, 4922-4925 (2001)
DOI: 10.1128/AEM.67.10.4922-4925.2001
52. N.L. Rani, D. Lalithakumari: Degradation of methyl parathion by *Pseudomonas putida*. *Can J Microbiol* 40, 1000-1006 (1994)
DOI: 10.1139/m94-160
53. J.J. DeFrank, T. Cheng: Purification and properties of an organophosphorus acid anhydrase from a halophilic bacterial isolate. *J. Bacteriol* 173, 1938-1943 (1991)
DOI: 10.1128/jb.173.6.1938-1943.1991
54. T. Cheng, L. Liu, B. Wang, J. Wu, J.J. DeFrank, D.M. Anderson, V.K. Rastogi, A.B. Hamilton: Nucleotide sequence of a gene encoding an organophosphorus nerve agent degrading enzyme from *Alteromonas haloplanktis*. *J Ind Microbiol Biotechnol* 18(1), 49-55 (1997)
DOI: 10.1038/sj.jim.2900358
55. I. Horne, T.D. Sutherland, R.L. Harcourt, R.J. Russell, J.G. Oakeshott: Identification of an opd (organophosphate degradation) gene in an *Agrobacterium* isolate. *Appl Environ Microbiol* 68, 3371-3376 (2002)
DOI: 10.1128/aem.68.7.3371-3376.2002
56. F.C.G. Hoskin, R.J. Long: Purification of a DFP-hydrolyzing enzyme from squid head ganglion. *Arch Biochem Biophys* 150, 548-555 (1972)
DOI: 10.1016/0003-9861(72)90073-2
57. C.E. Furlong, R.J. Richter, C. Chapline, J.W. Crabb: Purification of rabbit and human serum paraoxonase. *Biochemistry* 30, 10133-10140 (1991)

- DOI: 10.1021/bi00106a009
58. Y.J. Dong, M. Bartlam, L. Sun, Y.F. Zhou, Z.P. Zhang, C.G. Zhang, Z. Rao, X.E. Zhang: Crystal structure of methyl parathion hydrolase from *Pseudomonas* sp. WBC-3. *J Mol Biol* 353, 655–663 (2005)
DOI: 10.1016/j.jmb.2005.08.057
59. G.A. Omburo, J.M. Kuo, L.S. Mullins, F.M. Raushel: Characterization of the zinc binding site of bacterial phosphotriesterase. *J Biol Chem* 267, 13278–13283 (1992)
60. J. Hartleib, S. Geschwindner, E.I. Scharff, H. Ruterjans: Role of calcium ions in the structure and function of the diisopropylfluorophosphatase from *Loligo vulgaris*. *Biochem. J* 353, 579–589 (2001)
DOI: 10.1042/0264-6021:3530579
61. N.K. Vyas, A. Nickitenko, V.K. Rastogi, S.S. Shah, F.A. Quiocho: Structural insights into the dual activities of the nerve agent degrading organophosphate anhydrolase/ prolidase. *Biochemistry* 49, 547–559 (2010)
DOI: 10.1021/bi9011989
62. M. Harel, A. Aharoni, L. Gaidukov, B. Brumshtein, O. Khersonsky, R. Meged, H. Dvir, R.B.G. Ravelli, A. McCarthy, L. Toker, I. Silman, J.L. Sussman, D.S. Tawfik: Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. *Nat Struct Mol Biol* 11, 412–419 (2004)
DOI: 10.1038/nsmb767
63. M. Chen-Goodspeed, M.A. Sogorb, F. Wu, F.M. Raushel: Enhancement, relaxation, and reversal of the stereoselectivity for phosphotriesterase by rational evolution of active site residues. *Biochemistry* 40, 1332–1339 (2001)
DOI: 10.1021/bi001549d
64. X. Hu, X. Jiang, D.E. Lenz, D.M. Cerasoli, A. Wallqvist: In silico analyses of substrate interactions with human serum paraoxonase 1. *Proteins* 75, 486–498 (2009)
DOI: 10.1002/prot.22264
65. V. Katsemi, C. Lucke, J. Koepke, F. Lohr, S. Maurer, G. Fritzsche, H. Ruterjans: Mutational and structural studies of the diisopropylfluorophosphatase from *Loligo vulgaris* shed new light on the catalytic mechanism of the enzyme, *Biochemistry* 44, 9022–9033 (2005)
DOI: 10.1021/bi0500675
66. M.M. Blum, F. Lohr, A. Richardt, H. Ruterjans, J.C.H. Chen: Binding of a designed substrate analogue to diisopropyl fluorophosphatase: Implications for the phosphotriesterase mechanism. *J Am Chem Soc* 128, 12750–12757 (2006)
DOI: 10.1021/ja061887n
67. J. Koepke, E.I. Scharff, C. Lucke, H. Ruterjans, G. Fritzsche: Statistical analysis of crystallographic data obtained from squid ganglion DFPase at 0.85 Å resolution. *Acta Crystallogr D Biol Crystallogr* 59, 1744–1754 (2003)
DOI: 10.1107/S09074444903016135
68. M.M. Blum, M. Mustyakimov, H. Ruterjans, K. Kehe, B.P. Schoenborn, P. Langan, J.C.H. Chen: Rapid determination of hydrogen positions and protonation states of diisopropyl fluorophosphatase by joint neutron and X-ray diffraction refinement. *Proc Natl Acad Sci USA* 106, 713–718 (2009)

- DOI: 10.1073/pnas.0807842106
69. H. Yang, P.D. Carr, S.Y. McLoughlin, J.W. Liu, I. Horne, X. Qui, C.M.J. Jeffries, R.J. Russell, J.G. Oakeshott, D.L. Ollis Evolution of an organophosphate-degrading enzyme: A comparison of natural and directed evolution. *Protein Eng* 16, 135–145 (2003)
DOI: 10.1093/proeng/gzg013
70. S.R. Caldwell, J.R. Newcomb, K.A. Schlecht, F.M. Raushel: Limits of diffusion in the hydrolysis of substrates by the phosphotriesterase from *Pseudomonas diminuta*. *Biochemistry* 30, 7438–7444 (1991)
DOI: 10.1021/bi00244a010
71. C. Nowlan, Y. Li, J.C. Hermann, T. Evans, J. Carpenter, E. Ghanem, B.K. Shoichet, F.M. Raushel: Resolution of chiral phosphate, phosphonate, and phosphineate esters by an enantioselective enzyme library. *J Am Chem Soc* 128, 15892–15902 (2006)
DOI: 10.1021/ja0658618
72. L.M. Watkins, H.J. Mahoney, J.K. McCulloch, F.M. Raushel: Augmented hydrolysis of diisopropyl fluorophosphate in engineered mutants of phosphotriesterase. *J Biol Chem* 272, 25596–25601 (1997)
DOI: 10.1074/jbc.272.41.25596
73. M.Y. Chae, J.F. Postula, F.M. Raushel: Stereospecific enzymatic hydrolysis of phosphorus-sulfur bonds in chiral organophosphate triesters. *Bioorg Med Chem Let* 4, 1473–1478 (1994)
DOI: 10.1016/S0960-894X(01)80516-3
74. K. Lai, N.J. Stolowich, J.R. Wild: Characterization of P-S bond hydrolysis in organophosphorothioate pesticides by organophosphorus hydrolase. *Arch Biochem Biophys* 318(1), 59–64 (1995)
DOI: 10.1006/abbi.1995.1204
75. V.K. Rastogi, J.J. DeFrank, T. Cheng, J.R. Wild: Enzymatic hydrolysis of Russian-VX by organophosphorus hydrolase. *Biochem Biophys Res Commun* 241, 294–296 (1997)
DOI: 10.1006/bbrc.1997.7569
76. K.H. Lai, J.K. Grimsley, B.D. Kuhlmann, L. Scapozza, S.P. Harvey, J.J. DeFrank, J.E. Kolakowski, J.R. Wild: Rational enzyme design: computer modeling and site-directed mutagenesis for the modification of catalytic specificity in organophosphorus hydrolase. *Chimia* 50, 430–431 (1996)
77. S.B. Hong, F.M. Raushel: Metal-substrate interactions facilitate the catalytic activity of the bacterial phosphotriesterase. *Biochemistry* 35, 10904–10912 (1996)
DOI: 10.1021/bi960663m
78. J.L. Vanhooke, M.M. Benning, F.M. Raushel, H.M. Holden: Three-dimensional structure of the zinc-containing phosphotriesterase with the bound substrate analog diethyl 4-methylbenzylphosphonate. *Biochemistry* 35, 6020–6025 (1996)
DOI: 10.1021/bi960325l
79. S.B. Hong, F.M. Raushel: Stereochemical constraints on the substrate specificity of phosphotriesterase. *Biochemistry* 38, 1159–1165 (1999a)
DOI: 10.1021/bi982204m
80. S.B. Hong, F.M. Raushel: Stereochemical preference for chiral substrates by the bacterial

- phosphotriesterase. *Chem Biol Interact* 119 – 120, 225–234 (1999b)
DOI: 10.1016/s0009-2797(99)00031-9
81. V.E. Lewis, W.J. Donarski, F.M. Raushel: The Mechanism and Stereochemical Course at Phosphorus of the Reaction Catalyzed by a Bacterial Phosphotriesterase. *Biochemistry* 27, 1591-1597 (1988)
DOI: 10.1021/bi00405a030
82. E. Ghanem, F.M. Raushel: Detoxification of organophosphate nerve agents by bacterial phosphotriesterase. *Toxicol Appl Pharmacol* 207(2), 459-70 (2005)
DOI: 10.1016/j.taap.2005.02.025
83. F.M. Raushel: Bacterial detoxification of organophosphate nerve agents. *Curr Opin Microbiol* 5(3), 288-95 (2002)
DOI: 10.1016/s1369-5274(02)00314-4
84. H.P. Benschop, L.P.A. De Jong: Nerve agent stereoisomers: analysis, isolation and toxicology. *Acc Chem Res* 21, 368–374 (1988)
DOI: 10.1021/ar00154a003
85. P.C. Tsai, A.N. Bigley, Y. Li, E. Ghanem, C.L. Cadieux, S.A. Kasten, T.E. Reeves, D.M. Cerasoli, F.M. Raushel: Stereoselective hydrolysis of organophosphate nerve agents by the bacterial phosphotriesterase. *Biochemistry* 49, 7978 (2010)
DOI: 10.1021/bi101056m
86. C.M. Hill, W.S. Li, T.C. Cheng, J.J. DeFrank, F.M. Raushel: Stereochemical Specificity of Organophosphorus Acid Anhydrolase toward p-Nitrophenyl Analogs of Soman and Sarin. *Bioorg Chem* 29(1), 27–35 (2001)
DOI: 10.1006/bioo.2000.1189
87. F.C. Hoskin, B.J. Gallo, D.M. Steeves, J.E. Walker: Stereoselectivity of soman detoxication by organophosphorus acid anhydrases from *Escherichia coli*. *Chem Biol Interact* 87(1-3), 269-78 (1993)
DOI: 10.1016/0009-2797(93)90054-3
88. W.F. Li, K.T. Lum, M. Chen-Goodspeed, M.A. Sogorb, F.M. Raushel: Stereoselective detoxification of chiral sarin and soman analogues by phosphotriesterase. *Bioorg Med Chem* 9, 2083–2091 (2001)
DOI: 10.1016/s0968-0896(01)00113-4
89. S.P. Harvey, J.E. Kolakowski, T.C. Cheng, V.K. Rastogi, L.P. Reiff, J.J. DeFrank, F.M. Raushel, C. Hill: Stereospecificity in the enzymatic hydrolysis of cyclosarin (GF). *Enzyme Microbiol Technol* 37, 547–555 (2005)
DOI: 10.1016/j.enzmictec.2005.04.004
90. P.C. Tsai, N. Fox, A.N. Bigley, S.P. Harvey, D.P. Barondeau, F.M. Raushel: Enzymes for the homeland defense: Optimizing phosphotriesterase for the hydrolysis of organophosphate nerve agents. *Biochemistry* 51, 6463 (2012)
DOI: 10.1021/bi300811t
91. A.N. Bigley, C. Xu, T.J. Henderson, S.P. Harvey, F.M. Raushel: Enzymatic Neutralization of the Chemical Warfare Agent VX: Evolution of Phosphotriesterase for Phosphorothiolate Hydrolysis. *J Am Chem Soc* 135(28), 10426-32 (2013)
DOI: 10.1021/ja402832z
92. N. Martinelli, R. Micaglio, L. Consoli, P. Guarini, E. Grison, F. Pizzolo, S. Friso, E. Trabetti, P.F. Pignatti, R. Corrocher, O. Olivieri, D. Girelli: Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence

- the metabolic-syndrome-related risk of coronary artery disease. *Exp Diabetes Res* 2012:231502 (2012)
DOI: 10.1155/2012/231502
93. Z. Hashim, A. Ilyas, A. Saleem, A. Salim, S. Zarina: Expression and activity of paraoxonase 1 in human cataractous lens tissue. *Free Radic Biol Med* 46(8), 1089-95 (2009)
DOI: 10.1016/j.freeradbiomed-2009.01.012
94. B. Mackness, R. Beltran-Debon, G. Aragonés, J. Joven, J. Camps, M. Mackness: Human tissue distribution of paraoxonases 1 and 2 mRNA. *IUBMB Life* 62(6), 480-2 (2010)
DOI: 10.1002/iub.347
95. S.L. Primo-Parmo, R.C Sorenson, J. Teiber, B. La Du: The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. *Genomics* 33(3), 498-507 (1996)
DOI: 10.1006/geno.1996.0225
96. L. Rodrigo, B. Mackness, P.N. Durrington, A. Hernandez, M.I. Mackness: Hydrolysis of platelet-activating factor by human serum paraoxonase. *Biochem J* 354, 1-7 (2001)
DOI: 10.1042/0264-6021:3540001
97. J. Marsillach, G. Aragonès, R. Beltrán, J. Caballeria, J. Pedro-Botet, C. Morcillo-Suárez, A. Navarro, J. Joven, J. Camps: The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. *Clin Biochem* 42(1-2), 91-8. (2009)
DOI: 10.1016/j.clinbiochem.2008.09.120
98. C. Hassett, R.J. Richter, R. Humbert, C. Chapline, J.W. Crabb, C.J. Omiecinski, and C.E. Furlong: Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence. *Biochemistry* 30, 10141-10149 (1991)
DOI: 10.1021/bi00106a010
99. D. Josse, P. Masson: Human plasma paraoxonase (HuPON1): an anti-atherogenic enzyme with organophosphate hydrolase activity. *Ann Pharm Fr* 59(2), 108-18 (2001)
100. M.I. Mackness, B. Mackness, P.N. Durrington, P.W. Connelly, and R.A. Hegele: Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. *Curr Opin Lipidol* 7(2), 69-76 (1996)
DOI: 10.1097/00041433-199604000-00004
101. R.C. Sorenson, C.L. Bisgaier, M. Aviram, C. Hsu, S. Billecke, B.N. La Du: Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal Leader sequence associates with hdl's by binding phospholipids: Apolipoprotein A-I stabilizes activity. *Arterioscler Thromb Vasc Biol* 19, 2214-2225 (1999)
DOI: 10.1161/01.atv.19.9.2214
102. O. Khersonsky, D. Tawfik: Structure-reactivity of serum paraoxonasa PON 1 suggest that its native activity is lactonase. *Biochemistry* 44 (16), 6371-6382 (2005)
DOI: 10.1021/bi047440d
103. S. Billecke, D. Draganov, R. Counsell, P. Stetson, C. Watson, C. Hsu, B.N. La Du: Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. *Drug Metab Dispos* 28(11), 1335-42. (2000)

104. L.G. Costa, A. Vitalone, T. Cole, C.E. Furlong: Modulation of paraoxonase (PON 1) activity. *Biochem Pharmacol* 69, 541-550 (2005)
DOI: 10.1016/j.bcp.2004.08.027
105. Furlong CE, R R, Li W-F, Brophy VH, Carlson C, Meider M, Nickerson D, Costa LG, Ranchalis J, Lusi AJ, Shih DM, Tward A, Jarvik GP. The functional consequences of polymorphisms in the human PON1 gene. In: M M, Mackness B, Aviram M, Paragh G, editors. *The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism*. Springer; Dordrecht, The Netherlands (2008)
106. H. Jakubowski: Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. *J Biol Chem* 275(6), 3957-62 (2000)
DOI: 10.1074/jbc.275.6.3957
107. J.F. Teiber, D.I. Draganov, B.N. La Du: Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. *Biochem Pharmacol* 66, 887-896 (2003)
DOI: 10.1016/s0006-2952(03)00401-5
108. C.E. Furlong, R.J. Richter, S.L. Seidel, L.G. Costa, and A.G. Motulsky: Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. *Anal Biochem* 180(2), 242-7 (1989)
DOI: 10.1016/0003-2697(89)90424-7
109. A. Smolen, H.W. Eckerson, K.N. Gan, N. Hailat, B.N. La Du: Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. *Drug Metab Dispos* 19(1), 107-12 (1991)
110. H.G. Davies, R.J. Richter, M. Keifer, C.A. Broomfield, J. Sowalla, and C.E. Furlong: The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. *Nat Genet* 14, 334-336 (1996)
DOI: 10.1038/ng1196-334
111. A.L. Pond, H.W. Chambers, C.P. Coyne, J.E. Chambers: Purification of two rat hepatic proteins with A-esterase activity toward chlorpyrifos-oxon and paraoxon. *J Pharmacol Exp Ther* 286, 1404-1411 (1998)
112. C.J. Brealey, C.H. Walker, B.C. Baldwin: A esterase activities in relation to the differential toxicity of pirimiphos-methyl to birds and mammals. *Pestic Sci* 11, 546-554 (1980)
DOI: 10.1002/ps.2780110512
113. S. B. McCollister, R. J. Kociba, C. G. Humiston, D. D. McCollister, P. J. Gehring: Studies of the acute and long-term oral toxicity of chlorpyrifos (O, O-diethyl-O- (3, 5, 6-trichloro-2-pyridyl) phosphorothioate). *Food Cosmet Toxicol* 12, 45-61(1974)
DOI: 10.1016/0015-6264(74)90321-6
114. L.G. Costa, R.J. Richter, S.D. Murphy, G.S. Omenn, A.G. Motulsky, C.E. Furlong: Species differences in serum paraoxonase correlate with sensitivity to paraoxon toxicity. In: *Toxicology of Pesticides: Experimental Clinical and Regulatory Perspectives*, Costa LG, Galli CL, Murphy SD (Eds.). Springer: Heidelberg, 93-107 (1987)
115. W.F. Li, L.G. Costa, R.J. Richter, T. Hagen, D.M. Shih, A. Tward, A.J. Lusi, C.E. Furlong: Catalytic efficiency determines the in-vivo efficacy of PON1

- for detoxifying organophosphorus compounds. *Pharmacogenetics* 10(9):767-79 (2000)
DOI: 10.1097/00008571-200012000-00002
116. L.G Costa, B.E. McDonal, S.D. Murphy, G.S. Omenn, R.J. Richter, A.G. Motulsky, C.E. Furlong: Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. *Toxicol Appl Pharmacol* 103(1), 66-76 (1990)
DOI: 10.1016/0041-008x(90)90263-t
117. W.F. Li, L.G. Costa, C.E. Furlong: Serum paraoxonase status: a major factor in determining resistance to organophosphates. *J Toxicol Environ Health* 40(2-3), 337-46 (1993)
DOI: 10.1080/15287399309531798
118. W.F. Li, C.E. Furlong, L.G. Costa: Paraoxonase protects against chlorpyrifos toxicity in mice. *Toxicol Lett* 76(3), 219-26 (1995)
DOI: 10.1016/0378-4274(95)80006-Y
119. S.M. Chanda, S.R. Mortensen, V.C. Moser, S. Padilla: Tissue specific effects of chlorpyrifos on carboxylesterase and cholinesterase activity in adult rats: An *in vitro* and *in vivo* comparison. *Fundam Appl Toxicol* 38, 148-157 (1997)
DOI: 10.1006/faat.1997.2329
120. S. Karanth, C. Pope: Carboxylesterase and Aesterase activities during maturation and aging: Relationship to the toxicity of chlorpyrifos and parathion in rats. *Toxicol Sci* 58, 282-289 (2000)
DOI: 10.1093/toxsci/58.2.282
121. S.M. Chanda, T.L. Lassiter, V.C. Moser, S. Barone, S. Padilla: Tissue carboxylesterases and chlorpyrifos toxicity in the developing rat. *Hum. Ecol. Risk Assess* 8, 75-90 (2002)
DOI: 10.1080/20028091056737
122. R.F. Mueller, S. Hornung, C.E. Furlong, J. Anderson, E.R. Giblett, A.G. Motulsky: Plasma paraoxonase polymorphism: A new enzyme assay, population, family, biochemical, and linkage studies. *Am J Hum Genet* 35(3), 393- 408 (1983)
123. C.E. Furlong, N. Holland, R.J. Richter, A. Bradman, A. Ho, B. Eskenazi: PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. *Pharmacogenet Genomics* 16(3), 183-90 (2006)
DOI: 10.1097/01.fpc.0000189-796.21770.d3
124. K. Huen, K. Harley, A. Bradman, B. Eskenazi, H. Nina: Longitudinal Changes in PON1 Enzymatic Activities in Mexican-American Mothers and Children with Different Genotypes and Haplotypes. *Toxicol Appl Pharmacol* 244(2), 181-189 (2010)
DOI: 10.1016/j.taap.2009.12.031
125. T.B. Cole, R.L. Jampsa, B.J. Walter, T.L. Arndt, R.J. Richter, D.M. Shih, A. Tward, A.J. Lusi, R.M. Jack, L.G. Costa, C.E. Furlong: Expression of human paraoxonase (PON1) during development. *Pharmacogenetics* 13(6), 357-64 (2003)
DOI: 10.1097/00008571-200306000-00007
126. V. Gonzalez, K. Huen, S. Venkat, K. Pratt, P. Xiang, K.G. Harley, K. Kogut, C.M. Trujillo, A. Bradman, B. Eskenazi, N.T. Holland: Cholinesterase and paraoxonase (PON1) enzyme activities in Mexican-American mothers and

- children from an agricultural community. *J Expo Sci Environ Epidemiol* 22(6), 641-8 (2012)
DOI: 10.1038/jes.2012.61
127. A. H. Glickman, K.D. Wing, J.E. Casida: Profenofos insecticide bioactivation in relation to antidote action and the stereospecificity of acetylcholinesterase inhibition, reactivation, and aging. *Toxicol Appl Pharmacol* 73, 16-22 (1984)
DOI: 10.1016/0041-008x(84)90047-4
128. M. Bertolazzi, S. Caroldi, A. Moretto, M. Lotti: Interaction of methamidophos with hen and human acetylcholinesterase and neuropathy target esterase. *Arch Toxicol* 65(7), 580-5 (1991)
DOI: 10.1007/BF01973720
129. J.M. Battershill, P.M. Edwards, and M.K. Johnson: Toxicological assessment of isomeric pesticides: a strategy for testing of chiral organophosphorus (OP) compounds for delayed polyneuropathy in a regulatory setting. *Food Chem Toxicol* 42, 1279-1285 (2004)
DOI: 10.1016/j.fct.2004.03.004
130. M. Johnson, D.J. Read: The influence of chirality on the delayed neuropathic potential of some organophosphorus esters: Neuropathic and prophylactic effects of stereoisomeric esters of ethyl phenylphosphonic acid (EPN oxon and EPN) correlate with quantities of aged and unaged. *Toxicol Appl Pharmacol* 90, 103-115 (1987)
DOI: 10.1016/0041-008x(87)90311-5
131. M.K. Johnson, E. Vilanova, D.J. Read: Biochemical and clinical test of the delayed neuropathic potential of some O alkyl O dichlorophenyl phosphoramidate analogues of methamidophos (O, S dimethyl phosphorothioamidate). *Toxicology* 54, 89-100 (1989)
DOI: 10.1016/0300-483x(89)90081-4
132. L. Li, S. Zhou, L. Jin, C. Zhang, W. Liu: Enantiomeric separation of organophosphorus pesticides by high-performance liquid chromatography, gas chromatography and capillary electrophoresis and their applications to environmental fate and toxicity assays. *J Chromatogr B* 878, 1264-76 (2010)
DOI: 10.1016/j.jchromb.2009.10.031
133. Y.S. Wang, K.T. Tai, J.H. Yen: Separation, bioactivity, and dissipation of enantiomers of the organophosphorus insecticide fenamiphos. *Ecotoxicol Environ Saf* 57, 346-353 (2004)
DOI: 10.1016/j.ecoenv.2003.08.012
134. T. Cáceres, G.G. Ying, R. Kookana: Sorption of pesticides in banana production on soils of Ecuador. *Aust J Soil Res* 40, 1085-94 (2002)
DOI: 10.1071/SR02015
135. M. Megharaj, N. Singh, R. Kookana, R. Naidu: Hydrolysis of fenamiphos and its oxidation products by a soil bacterium in pure culture, soil and water. *Appl Microbiol Biotechnol* 61, 252-256 (2003)
DOI: 10.1007/s00253-002-1206-2
136. W. Liu, L. Kunde, G. Jianying: Separation and Aquatic Toxicity of Enantiomers of the Organophosphorus Insecticide Trichloronate. *Chirality* 18, 713-716 (2006)
DOI: 10.1002/chir.20323
137. C. Wang, N. Zhang, L. Li, Q. Zhang, M. Zhao, W. Liu: Enantioselective interaction with acetylcholinesterase of

- an organophosphate insecticide fenamiphos. *Chirality* 22(6), 612-7 (2010)
DOI: 10.1002/chir.20800
138. H. Leader, J.E. Casida: Resolution and biological activity of the chiral isomers of O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate. *J Agric Food Chem* 30, 546–551 (1982)
DOI: 10.1126/science.6849116
139. K.D. Wing, A.H. Glickman, J.E. Casida: (1983). Oxidative bioactivation of S-alkyl phosphorothiolate pesticides: stereospecificity of profenofos insecticide activation. *Science* 219(4580):63-5
DOI: 10.1126/science.6849116
140. H. Thiermann, L. Szinicz, F. Eyer, F. Worek, P. Eyer, N. Felgenhauer, T. Zilker: Modern strategies in therapy of organophosphate poisoning. *Toxicol Lett* 107(1-3), 233-9 (1999)
DOI: 10.1016/s0378-4274(99)00052-1
141. W.N. Aldridge: An enzyme hydrolysing diethyl p-nitrophenyl phosphate and identity with the A-esterase of mammalian sera. *Biochem J* 53, 117-124 (1953)
DOI: 10.1042/bj0530117
142. M.A. Sogorb, I. Sánchez, M. López-Rivadulla, V. Céspedes, E. Vilanova: EDTA-resistant and sensitive phosphotriesterase activities associated with albumin and lipoproteins in rabbit serum. *Drug Metab Dispos* 27(1), 53-9 (1999)
143. M.K. Johnson, D.J. Read: Stereospecific degradation of the R (+) isomer of O-Hexyl S Methylphosphorothioamidate catalysed by rabbit serum. *Chem Biol Interact* 87, 133-139 (1993)
DOI: 10.1016/0009-2797(93)90034-V
144. N. Díaz-Alejo, M.A. Sogorb, J.L. Vicedo, J. Barril, E. Vilanova: Non-calcium dependent activity hydrolysing organophosphorus compounds in hen plasma. *Comp Biochem Physiol Pharmacol Toxicol Endocrinol* 107(2), 213-9 (1994)
DOI: 10.1016/1367-8280(94)90043-4
145. A. Monroy-Noyola, M.A. Sogorb, E. Vilanova: Stereospecific hydrolysis of a phosphoramidate as a model to understand the role of biotransformation in the neurotoxicity of chiral organophosphorus compounds. *Toxicol Lett* 170, 157-164 (2007)
DOI: 10.1016/j.toxlet.2007.03.002
146. A. Monroy-Noyola, M.A. Sogorb, E. Vilanova: Enzyme concentration as an important factor in the *in vitro* testing of the stereospecificity of the enzymatic hydrolysis of organophosphorus compounds. *Toxicol In vitro* 13, 689-692 (1999)
147. S. Adkins, K.N. Gan, M. Mody, B.N. La Du: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B alloenzymes. *Am J Hum Genet* 52, 117-124 (1993)
148. C.E. Furlong: Genetic variability in the cytochrome P450-Paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds. *J Biochem Mol Toxicol* 21, 197–205 (2007)
DOI: 10.1002/jbt.20181
149. M. Jokanović: Current understanding of the mechanisms involved in metabolic detoxification of warfare nerve agents. *Toxicol Lett* 188, 1–10 (2009)
DOI: 10.1016/j.toxlet.2009.03.017

150. K.B. Augustinsson: Enzymatic Hydrolysis of Organophosphorus compounds. VII. The stereospecificity of phosphorylphosphatases. *Acta Chem Scand* 11, 1371-1377 (1957)
151. P.J. Christen, J.A. van den Muysenberg: The enzymatic isolation and fluoride catalysed racemisation of optically active Sarin. *Biochim Biophys Acta.* 110(1), 217-20 (1965)
DOI: 10.1016/s0926-6593(65)80117-5
152. P.J. Christen, De stereospecifieke enzymatische hydrolyse van sarin in plasma. Ph.D. thesis, State University of Leiden, The Netherlands, 1967
153. H.P. Benschop, L.P. De Jong: Toxicokinetics of soman: species variation and stereospecificity in elimination pathways. *Neurosci Biobehav Rev* 15(1), 73-7 (1991)
DOI: 10.1016/s0149-7634(05)80094-6
154. L.P. De Jong, H.P. Benschop, A. Due, C. Van Dijk, H.C. Trap, H.J. Van der Wiel, H.P. Van Helden: Soman levels in kidney and urine following administration to rat, guinea pig, and marmoset. *Life Sci* 50(14), 1057-62 (1992)
DOI: 10.1016/0024-3205(92)90101-t
155. G. Amitai, L. Gaidukov, R. Adani, S. Yishay, G. Yacov, M. Kushnir, S. Teitlboim, M. Lindenbaum, P. Bel, O. Khersonsky, D.S. Tawfik, H. Meshulam: Enhanced stereoselective hydrolysis of toxic organophosphates by directly evolved variants of mammalian serum paraoxonase. *FEBS J* 273, 1906-1919 (2006)
DOI: 10.1111/j.1742-4658.2006.05198.x
156. C.J. Van Dongen, J. De Lange, J. Van Genderen: *In vitro* degradation of the stereoisomers of soman in guinea-pig, mouse and human skin. *Biochem Pharmacol* 38(14), 2263-8 (1989)
DOI: 10.1016/0006-2952(89)90464-4
157. H.P. Benschop, F. Berends, L.P. De Jong: GLC-analysis and pharmacokinetics of the four stereoisomers of Soman. *Fundam Appl Toxicol* 1(2), 177-82 (1981)
DOI: 10.1016/s0272-0590(81)80056-5
158. H.P. Benschop, C.A. Konins, J. Van Genderen, L.P. De Jong: Isolation, *in vitro* activity, and acute toxicity in mice of the four stereoisomers of soman. *Fundam Appl Toxicol* 4, S84-S95 (1984)
DOI: 10.1016/0272-0590(84)90140-4
159. C. Herbert, J. Bisschop, R. Main, L. Jan, L. Williams: *In vitro* degradation of the four isomers of soman in human serum. *Biochem Pharmacol* 34, 1900-1905 (1987)
DOI: 10.1016/0006-2952(85)90305-3
160. L.P. De Jong, C. van Dijk, H.P. Benschop: Hydrolysis of the four stereoisomers of soman catalyzed by liver homogenate and plasma from rat, guinea pig and marmoset, and by human plasma. *Biochem Pharmacol* 37, 2939-2948 (1988)
DOI: 10.1016/0006-2952(88)90279-1
161. J. Little, C. Broomfield, M. Talbot, L. Boucher, B. MacIver, D. Lenz: Partial characterization of an enzyme that hydrolyzes sarin, soman, tabun, and diisopropyl phosphorofluoridate (DFP). *Biochem Pharmacol* 38, 23-29 (1989)
DOI: 10.1016/0006-2952(89)90144-5
162. H.C. De Bisschop, J.G. Mainil, J.L. Willems: *In vitro* degradation of four isomers soman in human serum.

- Biochem pharmacol* 34, 1985-1900 (1985)
DOI: 10.1016/0006-2952(85)90305-3
163. D.T. Yeung, J.R. Smith, R.E. Sweeney, D.E. Lenz, and D.M. Cerasoli: Direct detection of stereospecific soman hydrolysis by wild-type human serum paraoxonase. *FEBS J* 274, 1183–1191 (2007)
DOI: 10.1111/j.1742-4658.2006.05650.x
164. G. Amitai, R. Adani, G. Yacov, S. Yishay, S. Teitlboim, L. Tveria, O. Limanovich, M. Kushnir, H. Meshulam: Asymmetric fluorogenic organophosphates for the development of active organophosphate hydrolases with reversed stereoselectivity. *Toxicology* 233(1–3), 187–198 (2007)
DOI: 10.1016/j.tox.2006.09.020
165. T.C. Otto, S.A. Kasten, E. Kovaleva, Z. Liu, G. Buchman, M. Tolosa, D. Davis, J.R. Smith, R. Balcerzak, Lenz DE, Cerasoli DM: Purification and characterization of functional human paraoxonase-1 expressed in *Trichoplusia ni* larvae. *Chem Biol Interact* 187(1–3): 388–392 (2010)
DOI: 10.1016/j.cbi.2010.02.022
166. S.D. Kirby, J.R. Norris, J. Richard Smith, B.J. Bahnson, D.M. Cerasoli: Human paraoxonase double mutants hydrolyze V and G class organophosphorus nerve agents. *Chem Biol Interact* 203(1), 181-5 (2013)
DOI: 10.1016/j.cbi.2012.10.023
167. M. Goldsmith, Y. Ashani, Y. Simo, M. Ben-David, H. Leader, I. Silman, J.L. Sussman, D.S. Tawfik: Evolved Stereoselective Hydrolases for Broad-Spectrum G-Type Nerve Agent Detoxification. *Chem Biol* 19(4), 456–466 (2012)
DOI: 10.1016/j.chembiol.2012.01.017
168. R.D. Gupta, M. Goldsmith, Y. Ashani, Y. Simo, G. Mullokandov, H. Bar, M. Ben-David, H. Leader, R. Margalit, I. Silman, L.J. Sussman, and D.S. Tawfik: Directed evolution of hydrolases for prevention of G-type nerve agent intoxication. *Nat Chem Biol* 7, 120–125 (2011)
DOI: 10.1038/nchembio.510
169. A.M. Sogorb, A. Monroy, and E. Vilanova: Chicken serum albumin hydrolyzes dichlorophenyl phosphoramidates by a mechanism based on transient phosphorylation. *Chem Res Toxicol* 11(12), 1441-6 (1998)
DOI: 10.1021/tx980015z
170. D. Almenares-López, A. Monroy-Noyola: Copper (II)-dependent Hydrolysis of Trichloronate by Turkey Serum Albumin. *Chem Biol Interact* 308:252-257 (2019)
DOI: 10.1016/j.cbi.2019.05.039
171. D. Almenares-López. Hidrólisis de tricloronato por suero humano y de aves. Dissertation/master's thesis. Universidad Autónoma del Estado de Morelos, Morelos, México, 2010.
172. D. Almenares-López. Hidrólisis de fenamifos, profenofos y tricloronato por suero de aves e isoenzimas de PON1 Q192R de suero humano; Niveles de actividad, estereoselectividad y cinética. Dissertation/doctor's thesis. Universidad Autónoma Del Estado de Morelos, Morelos, México, (2014)

Abbreviations: OP(s): Organophosphorus compound(s); AChE: Acetylcholinesterase; NTE; neuropathy target esterase: OPIDP; Organophosphate-induced delayed

polyneuropathy syndrome: PTE(s);
Phosphotriesterase(s): PON1; Paraoxonase-1:
ACh; Acetylcholine: AChE; Acetylcho-
linesterase: BuChE; Butyrylcholinesterase:
HuBuChE; Human plasma butyrylcho-
linesterase: EPN; O-ethyl O-4-nitrophenyl
phenylphosphonothioate: VR; VR nerve agent:
OPAA; Organophosphorus acid anhydrolase:
VX; VX nerve agent: HDL; High-density
lipoprotein: PON1; Paraoxonase-1, HuPON1;
Human serum PON1: rHuPON1; Recombinant
human serum PON1: LD50; Lethal dose 50%:
EDTA; Ethylenediaminetetraacetic acid: HXM;
O-hexyl-S-methyl phosphoramidite: HDCP; O-
2,5-dichlorophenyl phosphoramidate: IMP-
pNP; O-isopropyl-O-(p-nitrophenyl) methyl
phosphonate: IMP-PNP; O-(isopropyl)-O-(p-
nitrophenyl)methyl phosphonate: E; Enantio-
meric ratio

Key Words: Chiral organophosphorus, Paraoxonase-1, Albumin, Stereoselectivity, Phosphotriesterases, A-esterases, Hydrolysis, Calcium. Copper, Nervous agent, Review

Send correspondence to: Antonio Monroy-Noyola, Laboratorio de Neuroproteccion, Facultad de Farmacia, Universidad Autonoma del Estado de Morelos, Av. Universidad 1001, Col, Chamilpa C.P. 62209, Cuernavaca, Morelos, Mexico, Tel: 52-777-329-79-89, Fax: 52-777-329-70-89, E-mail: amonroy@uaem.mx